Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • AChR
    (2)
  • Acyltransferase
    (1)
  • BCL
    (1)
  • Caspase
    (1)
  • GluR
    (1)
  • LPL Receptor
    (1)
  • Prostaglandin Receptor
    (2)
  • S1P Receptor
    (1)
  • Thrombin
    (3)
  • Others
    (7)
Filter
Search Result
Results for "

ischaemia

" in TargetMol Product Catalog
  • Inhibitor Products
    17
    TargetMol | Activity
  • Natural Products
    1
    TargetMol | inventory
NBQX
T4113118876-58-7
NBQX (FG9202) is a potent, selective and competitive AMPA receptor antagonist. Neuroprotective and anticonvulsant; active in vivo.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Ipratropium bromide monohydrate
T009866985-17-9
Ipratropium bromide monohydrate (Ipratropium bromide hydrate) is a muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Liriodenine
TN1875475-75-2
Liriodenine is a potent inhibitor of topoisomerase II (EC 5.99.1.3) both in vivo and in vitro, it has antitumor, antibacterial and antifungal activities, it can suppress ventricular arrhythmias induced by myocardial ischaemia reperfusion, through inhibiti
  • $540
Backorder
Size
QTY
TargetMol | Inhibitor Sale
Ozagrel hydrochloride
T662578712-43-3
Ozagrel hydrochloride (OKY-046 HCl) is a selective thromboxane A(2) synthetase inhibitor used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.
  • $43
In Stock
Size
QTY
TargetMol | Inhibitor Sale
NFPS
T16292405225-21-0
NFPS exerts neuroprotection via glyR alpha1 subunit in the rat model of transient focal cerebral ischaemia and reperfusion. NFPS is a selective and non-competitive glycine transporter-1 (GlyT1) inhibitor (IC50s: 2.8 nM and 9.8 nM for hGlyT1 and rGlyT1, respectively).
  • $660
35 days
Size
QTY
LY 215490
T27897150010-68-7
LY 215490 is a selective, competitive and systemically active antagonist of AMPA receptor. LY 215490 has neuroprotective effect against focal ischaemia in a model of permanent MCA occlusion in the rat.
  • $2,870
10-14 weeks
Size
QTY
VULM 1457
T23521228544-65-8
VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells.
  • $48
In Stock
Size
QTY
SEW​2871
T2171256414-75-2
SEW 2871 is an orally available, highly selective S1P1 agonist with an EC50 of 13.8 nM.It reduces the number of lymphocytes in the blood and is used in studies related to diabetes, Alzheimer's disease, liver fibrosis, and inflammation. It activates ERK, Akt and Rac signaling pathways and induces S1P1 internalization and recycling.
  • $48
In Stock
Size
QTY
Ozagrel
T623682571-53-7
Ozagrel (Domenan) is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet, used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.
  • $32
In Stock
Size
QTY
Ipratropium Bromide
T654722254-24-6
Ipratropium Bromide (Sch 1000) is a synthetic anticholinergic agent that is used as an inhalant for treatment of acute bronchospasm due to chronic bronchitis and emphysema.
  • $38
In Stock
Size
QTY
Pentisomide
T2593478833-03-1
Pentisomide is a class-I antiarrhythmic agent with a marked effect on depolarization (action of class Ia and Ic) and on repolarization. Pentisomide dose-dependently inhibited ischaemia-reperfusion arrhythmia. Pentisomide had been in phase II clinical trial for the treatment of arrhythmias.
  • $1,520
6-8 weeks
Size
QTY
Ifetroban sodium
T62924156715-37-6
Ifetroban (BMS-180291) sodium is an orally active thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor antagonist. It is used to study myocardial ischaemia, stroke, hypertension, thrombosis and cardiomyopathy.
  • $2,140
10-14 weeks
Size
QTY
BN 50739
T26875128672-07-1
BN 50739 is an antagonist of platelet-activating factor (PAF). BN 50739 suppresses certain cardiac arrhythmias. PAF is released from ischaemic myocardium and may contribute to initiation of ischaemia-induced ventricular fibrillation (VF)
  • $2,120
8-10 weeks
Size
QTY
Izilendustat hydrochloride
T630351303513-80-5
Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase that stabilizes hypoxia-inducible factor-1 alpha (HIF-1α) and hypoxia-inducible factor-2 (HIF-2). Potential for HIF-1α-related diseases (including peripheral vascular disease (PVD), heart failure, coronary artery disease (CAD), ischaemia, anaemia, colitis and other inflammatory bowel diseases).
  • $2,140
1-2 weeks
Size
QTY
AG-205
T71827442656-02-2
(rac)-AG-205 serves as a robust inhibitor of the progesterone receptor membrane component 1 (Pgrmc1), crucial for inducing genes linked to sterol synthesis, notably the INSIG1 protein, which interacts with PGRMC1. Additionally, it plays a pivotal role in mitigating neuronal resistance to hypoxic ischaemia by inhibiting NF-kB signalling and the activation of the BDNF/PI3K/AKT pathway.
  • $458
35 days
Size
QTY
EGIS-8332
T69806220725-87-1
EGIS-8332 is a potent and selective non-competitive AMPA receptor antagonist. EGIS-8332 inhibits AMPA/kainate ion channels and cell death. EGIS-8332 inhibited AMPA currents in rat cerebellar Purkinje cells and inhibited the AMPA- and quisqualate-induced excitotoxicity in primary cultures of telencephalon neurons (IC(50)=5.1-9.0 microM), in vitro. EGIS-8332 seems suitable for further development for the treatment of epilepsy, ischaemia and stroke based on its efficacy in a variety of experimental disease models, and on its low side effect potential.
  • $1,520
6-8 weeks
Size
QTY
Liriodenine methiodide
T2574355974-07-7
Liriodenine methiodide shows antibacterial and antifungal activity against several microorganisms.
  • $1,520
6-8 weeks
Size
QTY